Last $0.0090 USD
Change Today +0.0004 / 4.65%
Volume 5.0K
NVDL On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

novadel pharma inc (NVDL) Snapshot

Open
$0.0090
Previous Close
$0.0086
Day High
$0.0090
Day Low
$0.0090
52 Week High
01/2/14 - $0.02
52 Week Low
06/19/13 - $0.0024
Market Cap
1.2M
Average Volume 10 Days
520.7K
EPS TTM
$-0.02
Shares Outstanding
134.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVADEL PHARMA INC (NVDL)

novadel pharma inc (NVDL) Related Bloomberg News

View More Bloomberg News

novadel pharma inc (NVDL) Related Businessweek News

No Related Businessweek News Found

novadel pharma inc (NVDL) Details

NovaDel Pharma Inc., a specialty pharmaceutical company, develops oral spray formulations for marketed pharmaceuticals. The company’s proprietary technology enables delivery of drugs into the bloodstream leading to onset of action and patient benefits. Its oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, and nausea. NovaDel Pharma’s marketed products include NitroMist for acute relief of an attack of angina pectoris, or acute prophylaxis of angina pectoris, due to coronary artery disease; and ZolpiMist for short-term treatment of insomnia. The company’s product candidates comprise Duromist, which is in preclinical development for erectile dysfunction; Zensana, which is in preclinical development for nausea; NVD-201, an oral spray formulation of sumatriptan in Phase 2/3 clinical trial to treat migraine headache; NVD-301, an oral spray formulation of midazolam in preclinical stage for the treatment of sedation during diagnostic, therapeutic, and endoscopic procedures; and ZolpiMist in Phase 1 clinical trial to treat middle of the night awakening. It has strategic license agreements with Talon Therapeutics, Inc., Kwang Dong Pharmaceuticals, and BioAlliance Pharma SA to develop and market Zensana; Manhattan Pharmaceuticals, Inc. for the company’s oral spray technology to deliver propofol for pre-procedural sedation; and Velcera Pharmaceuticals, Inc. for veterinary applications for marketed veterinary drugs. NovaDel Pharma also has agreements with Mist Acquisition, LLC, for the manufacturing and commercialization of the NitroMist lingual spray version of nitroglycerine; and ECR Pharmaceuticals Company, Inc. to manufacture and commercialize ZolpiMist. The company was formerly known as Flemington Pharmaceutical Corporation and changed its name to NovaDel Pharma Inc. in October 2002. NovaDel Pharma Inc. was founded in 1982 and is headquartered in Bridgewater, New Jersey.

novadel pharma inc (NVDL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

novadel pharma inc (NVDL) Key Developments

NovaDel Pharma Inc. Announces the Sale of its NitroMist New Drug Application, License and Intellectual Property to Mist Pharmaceuticals, LLC

NovaDel Pharma Inc. has sold its NitroMist(R) New Drug Application to Mist Pharmaceuticals, LLC. The transaction also includes the NovaDel patents and trademarks covered by NovaDel's license agreement with Akrimax Pharmaceuticals, LLC for US rights to NitroMist(R) as well as the license agreement itself. The consideration for the sale was the assumption of the FDA fees, interest and penalties relating to NitroMist(R) owed by NovaDel up to the closing of the transaction. These fees, interest and penalties approximate $2,400,000.

Novadel Pharma Inc., Special/Extraordinary Shareholders Meeting, Jul 19, 2013

Novadel Pharma Inc., Special/Extraordinary Shareholders Meeting, Jul 19, 2013. Agenda: To approved the sale of substantially all of the company's assets to Suda Ltd.; and to consider the approval for the liquidation and dissolution of the company.

Novadel To Sell Remaining Assets

Novadel Pharma Inc. is seeking buyer for its remaining assets. NovaDel is seeking a purchaser for its remaining assets, which includes the NitroMist, ZolpiMist intellectual property and licenses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVDL:US $0.01 USD +0.0004

NVDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVDL.
View Industry Companies
 

Industry Analysis

NVDL

Industry Average

Valuation NVDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVADEL PHARMA INC, please visit www.novadel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.